Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-1532
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Fludarabine Plus Cyclophosphamide and Rituximab in Waldenstrom Macroglobulinemia

Cancer
Cancer ResearchOncology
2011English

Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenstrom Macroglobulinemia as a Paradigm

Oncologist
Cancer ResearchMedicineOncology
2015English

A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia

Clinical Cancer Research
Cancer ResearchOncology
2012English

Waldenstrom Macroglobulinemia Presenting as Plasma Cell Leukemia Associated With Hyperviscosity Syndrome

Medical Science and Discovery
2018English

Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing–Neel Syndrome

Case Reports in Hematology
2019English

Efficacy of the Oral mTORC1 Inhibitor Everolimus in Relapsed or Refractory Indolent Lymphoma

American Journal of Hematology
Hematology
2017English

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Waldenstrom Macroglobulinemia: Evidence for a Graft-Versus-Lymphoma Effect

Haematologica
Hematology
2018English

Continuous Administration of the mTORC1 Inhibitor Everolimus Induces Tolerance and Decreases Autophagy in Mice

British Journal of Pharmacology
Pharmacology
2016English

Forskolin Increases the Effect of Everolimus on Aromatase Inhibitor-Resistant Breast Cancer Cells

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy